Pharmaceutical

Filter

Current filters:

None

Popular Filters

6601 to 6625 of 7006 results

EFPIA supports a new R&D model to tackle antimicrobial resistance

27-10-2011

A vote of the European Parliament’s Health Committee on the threat posed by antimicrobial resistance,…

Antibiotics and Infectious diseasesEuropePharmaceuticalPoliticsResearch

Neuroendocrine carcinoma therapeutics to see strong growth to 2017

27-10-2011

The global neuroendocrine carcinoma therapeutics market was worth $91 million in 2010, and is forecast…

Markets & MarketingOncologyPharmaceutical

GlaxoSmithKline posts solid 3rd-qtr results, in line with expectations; joins WIPO scheme

27-10-2011

UK pharma giant GlaxoSmithKline (LSE: GSK) seems to have overcome some of its problems, such exceptional…

FinancialGlaxoSmithKlinePharmaceuticalResearch

Bayer 3rd-qtr 2011 results show strong Pharma offsetting weakness in MatSci

27-10-2011

German pharma, crop and materials sciences group Bayer AG (BAY: DE) posted a healthy set of third-quarter…

BayerFinancialPharmaceutical

Draft guidance from UK’s NICE recommends Roche’s RoActemra for systemic JIA

27-10-2011

In final draft guidance published today, by the UK drugs watchdog the National Institute for Health and…

Anti-Arthritics/RheumaticsEuropePharmaceuticalPricingRegulation

Bayer halts regorafenib trial for colorectal cancer on good Ph III results

27-10-2011

USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced…

BayerOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibResearch

Bristol-Myers in licensing deal with Gilead for combination HIV pill

26-10-2011

US drug major Bristol-Myers Squibb (NYSE: BMY) has entered into a licensing accord with biotech firm…

Anti-viralsBiotechnologyBristol-Myers SquibbcobicistatGilead SciencesLicensingPharmaceuticalReyataz

Vectura shares fall as partner Novartis reports US delay for lung cancer drug

26-10-2011

Shares of UK-based Vectura (LSE: VEC) tumbled 22% at 66 pence on Tuesday, after the company revealed…

NovartisPharmaceuticalRegulationResearchRespiratory and PulmonarySeebriVectura

Benlysta to drive lupus drug market to $2.1 billion in 2020

26-10-2011

Driven primarily by the launch and uptake of Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineMarkets & MarketingPharmaceuticalRare diseases

28 pharma companies in USA entered potential pay-for-delay deals in FY 2011, says new FTC report

26-10-2011

In the 2011 fiscal year (12 months to September 30) pharmaceutical companies in the USA continued a recent…

GenericsNorth AmericaPatentsPharmaceuticalPolitics

Eli Lilly pulls sepsis drug Xigris off all markets, due to lack of efficacy

26-10-2011

US drug major Eli Lilly (NYSE: LLY) revealed yesterday that it is withdrawing its Xigris (drotrecogin…

Antibiotics and Infectious diseasesEli LillyMarkets & MarketingPharmaceuticalResearchXigris

Merck KGaA 3rd-qtr 2011 net profit up 7.5% despite “challenging environment”

26-10-2011

Germany’s Merck KGaA said this morning that total revenues grew 3.8% to 2.53 billion euros ($3.52…

FinancialMerck KGaAMerck SeronoPharmaceutical

Russian pharma producers unlikely to be able to start exports to EU

25-10-2011

The Russian pharmaceutical industry risks running into a crisis in the coming years, due to the failure…

EuropePharmaceuticalRegulation

Sanofi names David Meeker as chief executive of Genzyme; Exelixis hires former Genentech exec

25-10-2011

French drug major Sanofi (Euronext: SAN) has appointed David Meeker as chief executive of its USA-based…

BiotechnologycabozantinibExelixisGenzymeManagementPharmaceuticalSanofi

Novartis to slash jobs, as 3rd-qtr sales leap 18% and net income rises 7%

25-10-2011

Swiss drug major Novartis (NOVN: VX) reported third-quarter 2011 results with 18% (12% at constant currencies)…

FinancialNovartisPharmaceutical

Lundbeck gets US FDA backing for Onfi to treat severe type of seizures

25-10-2011

Danish drugmaker Lundbeck (LUND: DC) yesterday received approval from the US Food and Drug Administration…

clobazamLundbeckNorth AmericaOnfiPharmaceuticalRare diseasesRegulation

Arrowhead acquires RNA assets and site from Roche, which takes minority stake in the firm

25-10-2011

California, USA-based Arrowhead Research Corp Nasdaq: ARWR) said yesterday that it has acquired RNA therapeutics…

Arrowhead ResearchFinancialMergers & AcquisitionsPharmaceuticalRoche

Irish drugmakers argue against ESRI Budget Perspectives (2012) proposals

24-10-2011

Budget Perspectives 2012, a paper published last week by the Economic and Social Research Institute (ESRI),…

EuropeGenericsHealthcarePharmaceuticalPricing

6601 to 6625 of 7006 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top